CCXI Stock Overview
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$22.79|
|52 Week High||US$42.16|
|52 Week Low||US$9.53|
|1 Month Change||17.11%|
|3 Month Change||-24.21%|
|1 Year Change||137.64%|
|3 Year Change||94.62%|
|5 Year Change||230.29%|
|Change since IPO||107.18%|
Recent News & Updates
|CCXI||US Biotechs||US Market|
Return vs Industry: CCXI exceeded the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: CCXI exceeded the US Market which returned -12.9% over the past year.
|CCXI Average Weekly Movement||12.2%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: CCXI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: CCXI's weekly volatility (12%) has been stable over the past year.
About the Company
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis.
ChemoCentryx Fundamentals Summary
|CCXI fundamental statistics|
Is CCXI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CCXI income statement (TTM)|
|Cost of Revenue||US$77.56m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.98|
|Net Profit Margin||-514.64%|
How did CCXI perform over the long term?See historical performance and comparison
Is ChemoCentryx undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CCXI ($22.79) is trading below our estimate of fair value ($205.39)
Significantly Below Fair Value: CCXI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CCXI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CCXI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CCXI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CCXI is overvalued based on its PB Ratio (6.3x) compared to the US Biotechs industry average (1.5x).
How is ChemoCentryx forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CCXI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: CCXI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CCXI's is expected to become profitable in the next 3 years.
Revenue vs Market: CCXI's revenue (49.6% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: CCXI's revenue (49.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CCXI is forecast to be unprofitable in 3 years.
How has ChemoCentryx performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CCXI is currently unprofitable.
Growing Profit Margin: CCXI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CCXI is unprofitable, and losses have increased over the past 5 years at a rate of 45.3% per year.
Accelerating Growth: Unable to compare CCXI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CCXI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: CCXI has a negative Return on Equity (-54.36%), as it is currently unprofitable.
How is ChemoCentryx's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CCXI's short term assets ($351.6M) exceed its short term liabilities ($68.8M).
Long Term Liabilities: CCXI's short term assets ($351.6M) exceed its long term liabilities ($112.9M).
Debt to Equity History and Analysis
Debt Level: CCXI has more cash than its total debt.
Reducing Debt: Insufficient data to determine if CCXI's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CCXI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CCXI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is ChemoCentryx current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CCXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CCXI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CCXI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CCXI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CCXI has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thomas Schall (62 yo)
Dr. Thomas J. Schall, Ph.D. Founded ChemoCentryx Inc. in November 1996 and has been its Chief Executive Officer, President and Director since 1997. Dr. Schall focuses on the discovery and development of ch...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD8.98M) is above average for companies of similar size in the US market ($USD5.44M).
Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.
Experienced Management: CCXI's management team is considered experienced (2.8 years average tenure).
Experienced Board: CCXI's board of directors are considered experienced (8.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
ChemoCentryx, Inc.'s employee growth, exchange listings and data sources
- Name: ChemoCentryx, Inc.
- Ticker: CCXI
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.622b
- Shares outstanding: 71.19m
- Website: https://www.chemocentryx.com
Number of Employees
- ChemoCentryx, Inc.
- 835 Industrial Avenue
- Suite 600
- San Carlos
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/22 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.